<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25173" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Minimal Change Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zamora</surname>
            <given-names>Glenda</given-names>
          </name>
          <aff>Palms West Children's Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pearson-Shaver</surname>
            <given-names>Anthony L.</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Glenda Zamora declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anthony Pearson-Shaver declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25173.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Minimal change disease (MCD) is one of the most common causes of idiopathic nephrotic syndrome in children. In the past, MCD was given the labels "nil disease" or "lipoid nephrosis."In adults, MCD closely resembles. Focal Segmental Glomerulosclerosis (FSGS) under light microscopy. However, electron microscopy demonstrates abnormalities in podocyte or glomerular epithelial cells in both MCD and focal segmental glomerulosclerosis (FSGS).</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of minimal change disease.</p></list-item><list-item><p>Describe the evaluation of minimal change disease.</p></list-item><list-item><p>Overview the management options available for minimal change disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25173&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25173">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25173.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Minimal change disease (MCD) is one of the most common causes of idiopathic nephrotic syndrome in children. It accounts for 70% to 90% of children that present with nephrotic syndrome who are older than one year old as opposed to 10-15%&#x000a0;of adults who present with nephrotic syndrome.<xref ref-type="bibr" rid="article-25173.r1">[1]</xref>&#x000a0;Minimal change disease is distinctive for proteinuria that results in edema and intravascular volume depletion, with a good response to steroids. Minimal Change Disease has been labeled &#x0201c;minimal change lesion,&#x0201d; &#x0201c;nil disease,&#x0201d; and &#x0201c;lipoid nephrosis&#x000a0;(a description of lipid droplets in urine seen on light&#x000a0;microscopy).<xref ref-type="bibr" rid="article-25173.r2">[2]</xref>&#x000a0;Minimal change disease has a particularly good prognosis in pediatric patients.</p>
      </sec>
      <sec id="article-25173.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Mostly&#x000a0;minimal change disease is idiopathic (primary) but can occur secondary to exposure to other agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>Infections: Tuberculosis, syphilis, mycoplasma, ehrlichiosis, hepatitis C virus</p>
          </list-item>
          <list-item>
            <p>Neoplasms: Hematologic malignancies, including leukemia, Hodgkin and non-Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Allergy: Bee and medusa stings, cat fur, fungi, poison ivy, ragweed pollen, house dust</p>
          </list-item>
          <list-item>
            <p>Drugs: NSAIDs, lithium, antibiotics (ampicillin, cephalosporins), immunizations, and gamma interferon</p>
          </list-item>
          <list-item>
            <p>Other glomerular diseases: Associated with IgA nephropathy, SLE, type 1 DM, and HIV</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25173.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Minimal change disease has an incidence of 2&#x000a0;to 7 new cases per 100,000 children. The exact prevalence is unknown; however, it is estimated to be about 10&#x000a0;to 50 cases per 100,000 children.&#x000a0;A male predominance (2&#x000a0;to 1) is noted during childhood, which disappears&#x000a0;during the adolescent years. Minimal change disease is not common in adults, and the exact incidence is not known.<xref ref-type="bibr" rid="article-25173.r2">[2]</xref></p>
      </sec>
      <sec id="article-25173.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Minimal change disease presents with a nephrotic syndrome characterized by an increased renal membrane permeability and loss of protein (primarily albumin) due to damage to the glomerular filtration barrier (GFB). The GFB is composed of fenestrated endothelium (inner layer), the glomerular basement membrane (middle layer), and an outer epithelial layer composed of podocytes. Podocytes are&#x000a0;epithelial cells with large cell bodies and long&#x000a0;foot processes that run parallel along the outside of glomerular capillaries. The space between foot processes is interspersed by cell-to-cell junctions called slit diaphragms.<xref ref-type="bibr" rid="article-25173.r3">[3]</xref>&#x000a0;</p>
        <p>Glomerular filtration is both size-specific and charge-specific. The actin cytoskeleton of podocytes provides support to the GBM and regulates flow across the basement membrane depending on&#x000a0;hydrostatic pressures, molecular size, and molecular charge.<xref ref-type="bibr" rid="article-25173.r3">[3]</xref>&#x000a0;The apical and luminal membrane of the slit diaphragms and podocytes are coated with a sialoglycoprotein (podocalyxin) which contributes to repels negatively charged molecules such as albumin. The two outer layers of the glomerular basement membrane&#x000a0;are composed of heparin sulfate proteoglycans that&#x000a0;are also negatively charged and contribute to the&#x000a0;charge selectivity of the barrier.<xref ref-type="bibr" rid="article-25173.r4">[4]</xref>&#x000a0;Disruption&#x000a0;of this barrier leads to the proteinuria seen in nephrotic syndrome.</p>
        <p>The pathogenesis of MCD is not exactly known, but it is thought to be multifactorial. Several studies have focused on the integrity and biology of podocytes. Because the actin cytoskeleton of podocytes maintains the integrity of the podocytes&#x000a0;by supporting the cell body and foot processes, regulation of flow across the basement membrane is controlled by a series of interactions. As a result, multiple theories have been proposed to explain the cause&#x000a0;of&#x000a0;proteinuria in MCD.&#x000a0;Some of the proposed theories published&#x000a0;include T cell dysfunction/dysregulation that leads to cytokine release and upregulation of proteins, such as CD80 and C-mip that affects the integrity of podocytes, systemic circulating factors that disrupt podocyte function,&#x000a0;and B- cell activation (suspected due to the efficacy of anti- CD-20 monoclonal antibodies, such as rituximab).<xref ref-type="bibr" rid="article-25173.r5">[5]</xref><xref ref-type="bibr" rid="article-25173.r6">[6]</xref><xref ref-type="bibr" rid="article-25173.r7">[7]</xref></p>
      </sec>
      <sec id="article-25173.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Light microscopy of renal biopsy specimens from patients with MCD shows minimal to no change; however, electron microscopy reveals the effacement of&#x000a0;podocyte&#x000a0;foot processes.&#x000a0;To add to the conundrum,&#x000a0;immunofluorescent staining of biopsy specimens is negative, and&#x000a0;no immune complexes are evident.</p>
      </sec>
      <sec id="article-25173.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>An accurate&#x000a0;history and a thorough physical exam must be performed on each patient who presents with edema and proteinuria. Proteinuria and edema may be presenting symptoms of&#x000a0;other conditions such as diabetes mellitus, adverse medication effects, or systemic lupus erythematous. It is also important to consider the patient&#x02019;s age, family history, and recent illnesses.</p>
        <p>Patients with MCD commonly present with periorbital, scrotum, labia, and/or lower extremity edema. On exam, patients may demonstrate anasarca, pericardial or pleural effusion, ascites, and abdominal pain. An affected individual is an intravascularly volume depleted and maybe oliguric, which can lead to&#x000a0;acute kidney injury, a&#x000a0;finding most frequently noted in adults. Children&#x000a0;often present with severe infections (sepsis, pneumonia, and peritonitis) due to the depletion of immunoglobulin.<xref ref-type="bibr" rid="article-25173.r8">[8]</xref>&#x000a0;Minimal change disease in adults presents with hematuria, acute kidney injury, and hypertension.</p>
      </sec>
      <sec id="article-25173.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Glomerulonephritis&#x000a0;is associated with many&#x000a0;diagnoses that are differentiated by histopathology or clinical presentation.<xref ref-type="bibr" rid="article-25173.r9">[9]</xref>&#x000a0;To establish the etiology of glomerulonephritis, one must determine whether the patient presents with nephritic or nephrotic syndrome. Nephritic syndrome is associated with hematuria,&#x000a0; proteinuria, and hypertension. Nephrotic syndrome is associated with heavy proteinuria, hypoalbuminemia, peripheral edema, hyperlipidemia, and thrombotic disease.&#x000a0;The fluid status in patients with nephrotic syndrome alternates between hypovolemia and hypervolemia.&#x000a0;Hypovolemic patients may be referred to as "underfilled" due to the loss of albumin through proteinuria. Hypoalbuminemia leads to decreased oncotic pressure and fluid sequestration in the interstitial space.<xref ref-type="bibr" rid="article-25173.r10">[10]</xref>&#x000a0;Hypoalbuminemia and low oncotic pressure induce reflexes through the juxtaglomerular apparatus to compensate for intravascular fluid losses by increasing sodium absorption and water retention.&#x000a0;Patients with MCD are commonly hypovolemic (underfilled).</p>
        <p>Hypervolemia (overfill) associated with nephrotic syndrome is due to tubular dysregulation, which increases sodium absorption and water retention. In these patients, hypoalbuminemia and decreased oncotic pressure are not the cause of edema.&#x000a0; Therefore, it is important to understand each patient's volume status before initiating therapy that addresses edema. &#x000a0;</p>
        <p>In&#x000a0;children, MCD&#x000a0;is the most&#x000a0;common cause of idiopathic nephrotic syndrome.&#x000a0;Minimal change disease is the third most common cause of idiopathic nephrotic syndrome in&#x000a0;adults&#x000a0;after focal segmental glomerular sclerosis and membranous nephropathy. An early kidney biopsy is crucial&#x000a0;to making the&#x000a0;diagnosis of MCD in adults.<xref ref-type="bibr" rid="article-25173.r1">[1]</xref></p>
        <p>In&#x000a0;children,&#x000a0;MCD is primarily a clinical diagnosis, and biopsy&#x000a0;is only required in the presence of atypical clinical features:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age of onset before 1 or after12 years old</p>
          </list-item>
          <list-item>
            <p>Gross hematuria</p>
          </list-item>
          <list-item>
            <p>Low serum C3</p>
          </list-item>
          <list-item>
            <p>Marked Hypertension</p>
          </list-item>
          <list-item>
            <p>Elevated creatinine</p>
          </list-item>
          <list-item>
            <p>Renal failure without hypovolemia</p>
          </list-item>
          <list-item>
            <p>Positive history or serology for secondary causes</p>
          </list-item>
          <list-item>
            <p>Steroid resistance<xref ref-type="bibr" rid="article-25173.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>A successful response to steroids might be anticipated in children how to present with typical clinical findings of MCD and are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age 1-12 years old</p>
          </list-item>
          <list-item>
            <p>Normotensive</p>
          </list-item>
          <list-item>
            <p>Normal Renal Function</p>
          </list-item>
          <list-item>
            <p>+/- Microscopic hematuria</p>
          </list-item>
        </list>
        <p>
<bold>Basic labs:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Urinalysis/ Urine microscopy</bold>: Dipstick will show 3+/4+ proteinuria. A urine dipstick and urinalysis (UA) are often the initial tests obtained to screen for MCD.&#x000a0;In MCD, the urine typically looks frothy secondary to proteinuria, and the microscopy shows oval fat bodies and fatty casts. Dysmorphic RBCs, acanthocytes, abnormal casts, and proteinuria are findings suggestive of glomerular injury not frequently seen in MCD.<xref ref-type="bibr" rid="article-25173.r9">[9]</xref>&#x000a0;Keep in mind that a urine dipstick has its limitations. The dipstick cannot identify&#x000a0;the extent or type of proteinuria as it primarily detects albumin and does not detect low molecular weight proteins.<xref ref-type="bibr" rid="article-25173.r11">[11]</xref>&#x000a0;False-positive test results are noted in the presence of mucus, blood, pus, alkalinity, or&#x000a0;concentration.<xref ref-type="bibr" rid="article-25173.r12">[12]</xref>&#x000a0;A 24-hour urine collection is required to quantitate urinary protein.</p>
          </list-item>
          <list-item>
            <p><bold>Urine collection:&#x000a0;</bold>A spot protein/creatinine ratio greater than 200 mg/mmol in children and&#x000a0;protein/creatinine ratio&#x0003e;300-350mg/mmol in adults is consistent with nephrotic syndrome, as is a 24-hour urine collection that reveals a total protein&#x000a0;greater than 3&#x000a0;to 3.5 g/24hour in adults. A report of measuring protein output as gms/m2/hr accounts for differences in body mass. A measurement of&#x000a0;40mg/m2/hour or greater (1gm/m2/24hour) is indicative of proteinuria consistent with nephrotic syndrome in children. Microscopic hematuria is present in 10% to 30% of adults.<xref ref-type="bibr" rid="article-25173.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Complete metabolic panel (CMP): </bold>CMP&#x000a0;demonstrates a low total protein, low albumin (frequently &#x0003c;2.5 g/dl), and low total calcium&#x000a0;(ionized calcium binds to albumin, and albumin is low).</p>
          </list-item>
          <list-item>
            <p><bold>Complete blood count (CBC):</bold>&#x000a0;CBC<bold>&#x000a0;</bold>will show hemoconcentration and thrombocytosis. This is seen due to the intravascular volume contraction from fluid sequestration into the interstitial space.</p>
          </list-item>
          <list-item>
            <p><bold>Total cholesterol and triglyceride levels:&#x000a0;</bold>These&#x000a0;are increased due to an increase in hepatic lipoprotein synthesis as a result of low oncotic pressures.<xref ref-type="bibr" rid="article-25173.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Labs to rule out secondary causes:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antinuclear antibodies</p>
          </list-item>
          <list-item>
            <p>Hepatitis B and C serologic tests</p>
          </list-item>
          <list-item>
            <p>Serologic test for syphilis (e.g., rapid plasma reagin)</p>
          </list-item>
          <list-item>
            <p>HIV antibody test</p>
          </list-item>
          <list-item>
            <p>Complement levels (CH50, C3, C4)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25173.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The initial cornerstone treatment for&#x000a0;minimal change disease is steroids. Children frequently achieve remission with steroids within 4 weeks vs. adults&#x000a0;who achieve remission in&#x000a0;two months or more&#x000a0;<xref ref-type="bibr" rid="article-25173.r2">[2]</xref>.&#x000a0;The incidence of relapse is high in children and adults.</p>
        <p>
<bold>Children</bold>
</p>
        <p>Initial prednisone therapy is 60 mg/m^2(or 2 mg/kg) administered daily for 4-6 weeks (maximum dose, 60 mg/day), or 40 mg/m2/(or 1.5 mg/kg) on alternate days for 2-5 months taper. Reduce the dose by 5&#x000a0;mg/m2&#x000a0;to 10 mg/m2 each week for another four weeks, then stop, with a minimum duration of 12 weeks <xref ref-type="bibr" rid="article-25173.r14">[14]</xref>.</p>
        <p>
<bold>Adults</bold>
</p>
        <p>Initial prednisone treatment is 1mg/kg per day or 2 mg/kg/kg every other day (max 80mg/day or 120 mg every other day) for 4-16 weeks. Taper slowly over a course of 6 months after remission<xref ref-type="bibr" rid="article-25173.r13">[13]</xref>.</p>
        <p>
<bold>Patients Who Relapse Demonstrate the following</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Steroid resistance is noted as the persistence of proteinuria in children after 4 weeks of prednisone and after 16 weeks for adults.</p>
          </list-item>
          <list-item>
            <p>Frequent relapses occur, which are defined as two or more relapses in the first&#x000a0;six months of&#x000a0;presentation or&#x000a0;four or more relapses within any 12 months</p>
          </list-item>
          <list-item>
            <p>Steroid dependency is defined as relapses that occur during the tapering phase of steroid therapy or less than two weeks after&#x000a0;discontinuing steroids</p>
          </list-item>
          <list-item>
            <p>Relapse nephrosis -&#x000a0;&#x0003e; 2+ proteinuria on 3 consecutive days</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Prednisolone&#x000a0;</bold>should be restarted if there is a relapse: 2 mg/kg daily (maximum 60 mg) until in remission for 3 days, then 1.5 mg/kg alternate days for 4 weeks, then stop or taper the dose over 4-8 weeks.</p>
          </list-item>
        </list>
        <p>
<bold>For frequent relapses/ steroid-dependent (steroid-sparing agents)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cyclophosphamide:</bold>&#x000a0;the dose of 2 mg/kg/ day for 8&#x000a0;to 12 weeks (should be started after reaching remission with the steroid)- potential gonadal toxicity, alopecia, bone marrow suppression.</p>
          </list-item>
          <list-item>
            <p><bold>Cyclosporine:</bold>&#x000a0;At a dose of 4&#x000a0;to 5 mg/kg/day, usually for 1-2 years. Levels should be monitored after 1 to 2 weeks. Aim for a trough of 70&#x000a0;to 150. Can cause nephrotoxicity, hirsutism, hypertension, and gingival hyperplasia.</p>
          </list-item>
        </list>
        <p>If intolerant to the above-mentioned drugs, can give<bold>:</bold></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mycophenolate mofetil (MMF):</bold> Doses of 500&#x000a0;to 1000 mg two times a day for 1&#x000a0;to 2 years. Should be monitored for leukopenia.<xref ref-type="bibr" rid="article-25173.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Rituximab (chimeric monoclonal antibody):&#x000a0;</bold>375&#x000a0;mg/weekly for 1&#x000a0;to 4 doses.<xref ref-type="bibr" rid="article-25173.r15">[15]</xref>&#x000a0;Side effects such as fulminant myocarditis, pulmonary fibrosis, fatal&#x000a0;<italic toggle="yes">Pneumocystis jirovecii&#x000a0;</italic>infections, ulcerative colitis, and allergic reactions.<xref ref-type="bibr" rid="article-25173.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25173.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac: Heart failure</p>
          </list-item>
          <list-item>
            <p>Hepatic: Liver failure, hepatocellular cirrhosis</p>
          </list-item>
          <list-item>
            <p>Digestive: Protein-losing enteropathy, malnutrition</p>
          </list-item>
          <list-item>
            <p>Renal: acute Glomerulonephritis, renal failure</p>
          </list-item>
          <list-item>
            <p>Immune: Angioedema, anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Lymphatic: Primary/secondary lymphedema, congenital lymphedema</p>
          </list-item>
        </list>
        <p>These diagnoses present with edema secondary to decreased intravascular oncotic pressure.</p>
      </sec>
      <sec id="article-25173.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Minimal change disease has very good prognosis for all ages if there is a response to corticosteroid therapy. The&#x000a0;primary morbidity&#x000a0;is related to the adverse effects of the medications.<xref ref-type="bibr" rid="article-25173.r2">[2]</xref></p>
      </sec>
      <sec id="article-25173.s12" sec-type="Complications">
        <title>Complications</title>
        <p>These complications are mainly secondary to the extensive proteinuria that is seen with this disease.&#x000a0;</p>
        <p>Children and adults with MCD are at risk for developing complications such as:</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Hypovolemia</bold>
</p>
          </list-item>
          <list-item>
            <p><bold>Infections (pneumonia, peritonitis, sepsis):</bold> Secondary to the loss of immunoglobulins (IgG) and complement factors via the urine. Also, there is decreased opsonization of capsulated organisms.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Venous thromboembolism:</bold> due to a decrease in antithrombin III, protein S, plasminogen, and increase in prothrombotic factors.<xref ref-type="bibr" rid="article-25173.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>
<bold>Hyperlipidemia</bold>
</p>
          </list-item>
          <list-item>
            <p><bold>Acute kidney injury: </bold>From the intravascular volume depletion.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25173.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with acute and active disease should have low sodium in their diet and should also be encouraged to restrict their fluid intake.</p>
      </sec>
      <sec id="article-25173.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Minimal change disease is frequently encountered as the most common cause of nephrotic syndrome in children, and it is the third most common cause of nephrotic syndrome in adults. An interdisciplinary team including a nephrologist, pharmacist, primary care, and nurse is essential for detection, diagnosis, and optimizing therapy. In children, MCD presents with distinct clinical features. However, in adults, the clinical features may vary. It is important to recognize these clinical and lab findings associated with MCD to tailor and optimize therapy&#x000a0;in MCD&#x000a0;subgroups.</p>
      </sec>
      <sec id="article-25173.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25173&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25173">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/minimal-change-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25173">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25173/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25173">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25173.s16">
        <title>References</title>
        <ref id="article-25173.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crew</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Valeri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Adult minimal-change disease: clinical characteristics, treatment, and outcomes.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2007</year>
            <month>May</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>445</fpage>
            <page-range>445-53</page-range>
            <pub-id pub-id-type="pmid">17699450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vivarelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Massella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ruggiero</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Minimal Change Disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>07</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>332</fpage>
            <page-range>332-345</page-range>
            <pub-id pub-id-type="pmid">27940460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Downie</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gallibois</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Noone</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Nephrotic syndrome in infants and children: pathophysiology and management.</article-title>
            <source>Paediatr Int Child Health</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>248</fpage>
            <page-range>248-258</page-range>
            <pub-id pub-id-type="pmid">28914167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bonanni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caridi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Canepa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghiggeri</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>170</fpage>
            <pub-id pub-id-type="pmid">29942802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frank</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dirnecker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>B&#x000f6;swald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolowos</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ruder</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Dominant T cells in idiopathic nephrotic syndrome of childhood.</article-title>
            <source>Kidney Int</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>510</fpage>
            <page-range>510-7</page-range>
            <pub-id pub-id-type="pmid">10652027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiser</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Childress</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Shirkey</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>T-lymphocyte subsets in nephrotic syndrome.</article-title>
            <source>Kidney Int</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>913</fpage>
            <page-range>913-6</page-range>
            <pub-id pub-id-type="pmid">1762295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cara-Fuentes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Clapp</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Garin</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>2179</fpage>
            <page-range>2179-2189</page-range>
            <pub-id pub-id-type="pmid">27384691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shalhoub</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of lipoid nephrosis: a disorder of T-cell function.</article-title>
            <source>Lancet</source>
            <year>1974</year>
            <month>Sep</month>
            <day>07</day>
            <volume>2</volume>
            <issue>7880</issue>
            <fpage>556</fpage>
            <page-range>556-60</page-range>
            <pub-id pub-id-type="pmid">4140273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation &#x00026; management of glomerular diseases: hematuria, nephritic &#x00026; nephrotic syndrome.</article-title>
            <source>Mo Med</source>
            <year>2011</year>
            <season>Jan-Feb</season>
            <volume>108</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-6</page-range>
            <pub-id pub-id-type="pmid">21462608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology, Evaluation, and Management of Edema in Childhood Nephrotic Syndrome.</article-title>
            <source>Front Pediatr</source>
            <year>2015</year>
            <volume>3</volume>
            <fpage>111</fpage>
            <pub-id pub-id-type="pmid">26793696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viteri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reid-Adam</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hematuria and Proteinuria in Children.</article-title>
            <source>Pediatr Rev</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>573</fpage>
            <page-range>573-587</page-range>
            <pub-id pub-id-type="pmid">30504250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Utsch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Klaus</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Urinalysis in children and adolescents.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2014</year>
            <month>Sep</month>
            <day>12</day>
            <volume>111</volume>
            <issue>37</issue>
            <fpage>617</fpage>
            <page-range>617-25; quiz 626</page-range>
            <pub-id pub-id-type="pmid">25283761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The treatment of minimal change disease in adults.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>702</fpage>
            <page-range>702-11</page-range>
            <pub-id pub-id-type="pmid">23431071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lombel</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gipson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hodson</surname>
                <given-names>EM</given-names>
              </name>
              <collab>Kidney Disease: Improving Global Outcomes</collab>
            </person-group>
            <article-title>Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>415</fpage>
            <page-range>415-26</page-range>
            <pub-id pub-id-type="pmid">23052651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25173.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munyentwali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bouachi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Audard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Remy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mojaat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Desch&#x000ea;nes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Plaisier</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.</article-title>
            <source>Kidney Int</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>511</fpage>
            <page-range>511-6</page-range>
            <pub-id pub-id-type="pmid">23325085</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
